PAG Pays $540 Million for Majority Stake in Hisun BioRay, a Biologics Company
publication date: Sep 6, 2019
Following a bidding war, Hong Kong private equity firm PAG will pay $540 million to acquire a 58% stake in Hisun BioRay, a biologics company with a focus in autoimmune and oncology drugs. It is the largest private equity deal in China biopharma this year, according to the companies. BioRay is the biologics subsidiary of Zhejiang Hisun Pharma, a company that specializes in generic drugs and APIs. BioRay already markets an autoimmune treatment in China and is developing ten other biologics. More details....
Stock Symbols: (SHA: 600267)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.